Enzelkitug

Phase 1

Enzelkitug is one of 3 therapeutic programs targeting Locally Advanced or Metastatic Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Locally Advanced or Metastatic Solid TumorsRecruiting

Locally Advanced or Metastatic Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Locally Advanced or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 1

13 2

Keytruda

Merck & Co.

Phase 1

10 3

Enzelkitug

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Locally Advanced or Metastatic Solid Tumors

NCT05581004

Clinical

Trials by Indication[1]

Locally Advanced or Metastatic Solid Tumors1 trial

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting· Roche logo

Roche·Phase 1·NCT05581004·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Enzelkitug. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Enzelkitug. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Roche

Enzelkitug

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Locally Advanced or Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News